No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BDTX240621P7500
- 1.60
- +0.04+2.56%
15min DelayClose Jun 14 15:59 ET
1.60High1.60Low
1.60Open1.56Pre Close3 Volume13 Open Interest7.50Strike Price480.00Turnover0.00%IV1.17%PremiumJun 21, 2024Expiry Date1.53Intrinsic Value100Multiplier4DDays to Expiry0.07Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma3.91Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Form 144 | Black Diamond Therapeutics(BDTX.US) Insider Proposes to Sell 148.46K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 14, $Black Diamond Therapeutics(BDTX.US)$ Insider David Epstein intends to sell 24,621 shares of its common stock on Jun 14, with a total market value of approximately $148
Form 144 | Black Diamond Therapeutics(BDTX.US) Insider Proposes to Sell 435.75K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 13, $Black Diamond Therapeutics(BDTX.US)$ Insider David Epstein intends to sell 70,853 shares of its common stock on Jun 13, with a total market value of approximately $435
Form 144 | Black Diamond Therapeutics(BDTX.US) Insider Proposes to Sell 383.92K in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 12, $Black Diamond Therapeutics(BDTX.US)$ Insider David Epstein intends to sell 62,528 shares of its common stock on Jun 12, with a total market value of approximately $383
Here's Why We're Watching Black Diamond Therapeutics' (NASDAQ:BDTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Black Diamond Therapeutics (NASDAQ:BDTX) has seen its share price rise 181% over the la
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersElutia (NASDAQ:ELUT) stock rose 24.2% to $4.31 during Tuesday's regular session. The market value of their outstanding shares is at $104.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 20.6
Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Black Diamond Theraptcs Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Comments
Black Diamond Therapeutics: Analysis and Insights.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and gli...
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology medicine company focusing on the discovery and development of MasterKey therapies for patients with genetically defined tumors. Their main product candidate, BDTX-1535, is designed to treat brain-penetrant epidermal growth factor receptor (EGFR) mutations, notably in non-small cell lung cancer (NSCLC) and gli...
$Black Diamond Therapeutics(BDTX.US$
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics presented promising clinical data on its lead candidate BDTX-1535 at the 2024 ASCO Annual Meeting. The Phase 1 dose escalation trial in recurrent glioblastoma (GBM) patients showed a favorable safety profile and encouraging anti-tumor activity, with sev...
Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Black Diamond Therapeutics presented promising clinical data on its lead candidate BDTX-1535 at the 2024 ASCO Annual Meeting. The Phase 1 dose escalation trial in recurrent glioblastoma (GBM) patients showed a favorable safety profile and encouraging anti-tumor activity, with sev...
$Black Diamond Therapeutics(BDTX.US$
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
2
$Black Diamond Therapeutics(BDTX.US$ moving 👀 lot of 💰 holders at 5/6$ past spike !
Read more